FDA approves IND application for GNTbm-38 for Ph 1 trial in Advanced Solid Tumors and R/R PTCL
Dr. Chia-Nan Chen, Chairman of GNTbm, stated: “GNTbm-38 is a new generation anti-cancer immunotherapy drug independently developed by the GNTbm R&D team after years of experiences on developing new drug Kepida®.” GNTbm-38 is a brand new orally administered new chemical entity drug independently developed in Taiwan. GNTbm-38 has excellent epigenetic regulation and immune activation mechanisms, which can control the on-off switches of genes and further impact the expression of genes and proteins at a deeper level. The R&D team of GNTbm has already planned a clinical development strategy for multiple indications for GNTbm-38, prioritizing the development of relapsed or refractory peripheral T-cell lymphoma to obtain orphan drug designation; subsequently, new indications will be expanded. GNTbm-38 is a broad-spectrum, oral, anti-cancer new drug with immense development potential. It can be used in combination with drugs of different mechanisms, including unique multi-kinase inhibitors, immune checkpoint inhibitors, or anti-PD-1/VEGF bispecific antibodies, generating stronger synergistic anti-cancer effects and providing patients with better treatment benefits.
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us